A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
NCT ID: NCT01732198
Last Updated: 2013-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
220 participants
INTERVENTIONAL
2013-03-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Evaluate the immunogenicity, as determined by anti-PRP polysaccharide response, of a single booster dose of NU300 co-administered with Prevnar 13® compared to a single booster dose of ActHIB® co-administered with Prevnar 13®.
Evaluate the individual IgG antibody quantitative response to the 13 antigens in Prevnar 13® following NU300 co-administration with Prevnar 13® compared to the IgG antibody response to the pneumococcal polysaccharides following ActHIB® co-administration with Prevnar 13® 28 days following injection.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NU300 and Prevnar 13
NU300 at a single dose of 0.5 mL IM
NU300
Prevnar 13
ActHIB and Prevnar 13
ActHIB at a dose of 0.5 ml IM
ActHIB
Prevnar 13
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NU300
ActHIB
Prevnar 13
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female subjects 12-15 months of age at the time of booster vaccination, who had previously received complete primary vaccination series with a licensed Hib product and Prevnar 13® in accordance with the FDA approved labels.
3. Subjects for whom the investigator believes that the parent/guardian can and will comply with the requirements of the protocol
4. Subjects free of obvious health problems as established by medical history and clinical examination before entering the study
Exclusion Criteria
2. Any confirmed or suspected Haemophilus influenzae or pneumococcal illness.
3. Administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before and ending 28 days after administration of study vaccines (before the blood draw at Visit 2).
4. Chronic administration of immunosuppressants or other immune-modifying drugs within 30 days prior to dosing in the study.
5. Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and/or clinical examination.
6. Early pre-term birth (delivery before 32 weeks).
7. Major congenital defects or serious chronic diseases, or serious conditions including history of seizures, apnea, etc.
8. Concurrent participation in another clinical study at any time during the study period or within the previous 6 months in which the subject has been or will be exposed to an investigational or non-investigational product (pharmaceutical product, formula, or device)
9. Presence of a moderate or severe illness with or without fever at the time of vaccination (fever is defined as a temperature of ≥ 38.0C \[100.4F\]).
10. Known history of thrombocytopenia or any coagulation disorder.
11. Known hypersensitivity to any of the components of the vaccines.
12. Known hypersensitivity to latex.
13. The subject is unable to provide an adequate blood draw for immunogenicity assays, and safety panels at Visit 1
12 Months
15 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nuron Biotech Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oakland, California, United States
Bardstown, Kentucky, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP-NU300-02
Identifier Type: -
Identifier Source: org_study_id